{"id":5864,"date":"2025-03-07T17:04:03","date_gmt":"2025-03-07T14:04:03","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=5864"},"modified":"2025-03-07T17:04:13","modified_gmt":"2025-03-07T14:04:13","slug":"5864","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/5864\/","title":{"rendered":"Highlights: Comparison of ESC vs. ACC\/AHA ACS Guidelines"},"content":{"rendered":"
\n

\"\"<\/p>\n

Highlights: Comparison of ESC vs. ACC\/AHA ACS Guidelines<\/p>\n<\/div>\n

\u2022 Integration & Evidence Base:<\/span><\/div>\n
\u2022 ACC\/AHA: Combines data from multiple previous guidelines to form a unified, updated approach for ACS management.<\/span><\/div>\n
\u2022 ESC: Emphasizes early, aggressive intervention\u2014particularly in lipid management\u2014with targets such as LDL\u2011C <55\u202fmg\/dL.<\/span><\/div>\n
\u2022 Dual Antiplatelet Therapy (DAPT):<\/span><\/div>\n
\u2022 ACC\/AHA: Recommends at least 12 months of DAPT (aspirin plus a P2Y12 inhibitor), with ticagrelor or prasugrel preferred for PCI patients; supports transitioning to monotherapy after 1 month in selected cases.<\/span><\/div>\n
\u2022 ESC: Endorses 12-month DAPT as well but allows for de-escalation to single antiplatelet therapy after 3\u20136 months in patients at lower ischemic risk or higher bleeding risk.<\/span><\/div>\n
\u2022 Lipid Management:<\/span><\/div>\n
\u2022 ACC\/AHA: Advocates high\u2011intensity statin therapy for all ACS patients, with the addition of non\u2011statin agents (e.g., ezetimibe or PCSK9 inhibitors) if LDL\u2011C remains \u226570\u202fmg\/dL or for patients with LDL\u2011C in the 55\u201369\u202fmg\/dL range.<\/span><\/div>\n
\u2022 ESC: Also starts high\u2011intensity statins early but sets a more aggressive LDL\u2011C target (<55\u202fmg\/dL), with further intensification (e.g., aiming for <40\u202fmg\/dL) in recurrent events.<\/span><\/div>\n
\u2022 Revascularization Strategies:<\/span><\/div>\n
\u2022 ACC\/AHA: Recommends complete revascularization for stable patients with multivessel disease\u2014either during the index procedure or staged\u2014and advocates culprit\u2011only PCI in cardiogenic shock.<\/span><\/div>\n
\u2022 ESC: Supports complete revascularization in hemodynamically stable patients, favoring index\u2011procedure revascularization in STEMI, while recommending a cautious, staged approach in the setting of cardiogenic shock.<\/span><\/div>\n
\u2022 Bleeding Risk Management:<\/span><\/div>\n
\u2022 ACC\/AHA: Utilizes strategies such as proton pump inhibitor use, early transition to monotherapy, or de\u2011escalation in high\u2011bleeding\u2011risk patients; suggests discontinuing aspirin 1\u20134 weeks post\u2011PCI when combined with oral anticoagulation.<\/span><\/div>\n
\u2022 ESC: Adopts a similar risk\u2011adjusted approach with individualized DAPT duration and transitions based on bleeding risk profiles.<\/span><\/div>\n
\u2022 Implementation & Dissemination:<\/span><\/div>\n
\u2022 ACC\/AHA: Focuses on practical tools like central illustrations and comparison tables to enhance guideline adoption across clinical, educational, and policy domains.<\/span><\/div>\n
\u2022 ESC: Emphasizes streamlined protocols and clear targets to drive early and intensive intervention in ACS care.<\/span><\/div>\n
<\/div>\n
https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2025.01.018<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Highlights: Comparison of ESC vs. ACC\/AHA ACS Guidelines \u2022 Integration & Evidence Base: \u2022 ACC\/AHA: Combines data from multiple previous guidelines to form a unified, updated approach for ACS management. \u2022 ESC: Emphasizes early, aggressive intervention\u2014particularly in lipid management\u2014with targets such as LDL\u2011C <55\u202fmg\/dL. \u2022 Dual Antiplatelet Therapy (DAPT): \u2022 ACC\/AHA: Recommends at least 12 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5864","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=5864"}],"version-history":[{"count":2,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5864\/revisions"}],"predecessor-version":[{"id":5868,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5864\/revisions\/5868"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=5864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=5864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=5864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}